Cause-specific mortality in the general population with transient dipstick-proteinuria

Autoři: Kei Nagai aff001;  Kunihiro Yamagata aff001;  Kunitoshi Iseki aff002;  Toshiki Moriyama aff002;  Kazuhiko Tsuruya aff002;  Shouichi Fujimoto aff002;  Ichiei Narita aff002;  Tsuneo Konta aff002;  Masahide Kondo aff001;  Masato Kasahara aff002;  Yugo Shibagaki aff002;  Koichi Asahi aff002;  Tsuyoshi Watanabe aff002
Působiště autorů: University of Tsukuba, Tsukuba, Ibaraki, Japan aff001;  The Steering Committee for “Design of the Comprehensive Health Care System for Chronic Kidney Disease (CKD) Based on the Individual Risk Assessment by Specific Health Checkups”, Tsukuba, Ibaraki, Japan aff002;  Okinawa Heart and Renal Association, Okinawa, Japan aff003;  Health Care Center, Osaka University, Suita, Japan aff004;  Nara Medical University, Nara, Japan aff005;  University of Miyazaki, Miyazaki, Japan aff006;  Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan aff007;  Yamagata University Graduate School of Medical Science, Yamagata, Japan aff008;  Institute for Clinical and Translational Science, Nara Medical University Hospital, Nara, Japan aff009;  St. Marianna University School of Medicine, Kawasaki, Kanagawa, Japan aff010;  Iwate Medical University, Morioka, Japan aff011;  Fukushima Rosai Hospital, Iwaki, Japan aff012
Vyšlo v časopise: PLoS ONE 14(10)
Kategorie: Research Article
doi: 10.1371/journal.pone.0223005


Recently, changes in urinary albumin and in GFR have been recognized as risk factors for the development of end-stage kidney disease and mortality. Though most clinical epidemiology studies of chronic kidney disease (CKD) used renal function and proteinuria at baseline alone, definitive diagnosis of CKD with multiple measurements intensifies the differences in the risk for mortality between the CKD and non-CKD populations. We hypothesized that a transient diagnosis of proteinuria and reduced renal function each indicate a significantly higher mortality compared to definitive non-CKD as the negative control and lower mortality compared with definitive CKD as the positive control. The present longitudinal study evaluated a general-population cohort of 338,094 persons who received annual health checkups, with a median 4.3-year study period. There were 2,481 deaths, including 510 CVD deaths (20.6%) and 1,328 cancer deaths (53.5%), and mortality risk was evaluated for transient proteinuria and for transiently reduced renal function. The hazard ratios (HRs) for all-cause mortality and cancer mortality were not significant, but that for cardiovascular mortality was significantly higher for transient proteinuria (HR, 1.94 [95% confidence interval, 1.27–2.96] in men and 2.78 [1.50–5.16] in women). On the other hand, transiently reduced renal function was not significant for either cardiovascular mortality risk or cancer mortality risk. We surmise that this is the first study of the mortality risk of transient dipstick proteinuria in a large general-population cohort with cause-specific death registration. Transiently positive proteinuria appears to be a significant risk specifically for cardiovascular mortality compared with definitely negative for proteinuria.

Klíčová slova:

Antihypertensive drugs – Blood pressure – Cardiovascular diseases – Death rates – Glomerular filtration rate – Chronic kidney disease – Lipoproteins – Proteinuria


1. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004; 351: 1285–1295. doi: 10.1056/NEJMoa041365 15385655

2. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004; 15: 1307–1315. doi: 10.1097/01.asn.0000123691.46138.e2 15100371

3. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004; 351: 1296–1305. doi: 10.1056/NEJMoa041031 15385656

4. Muntner P, He J, Hamm L, Loria C, Whelton PK. Renal insufficiency and subsequent death resulting from cardiovascular disease in the United States. J Am Soc Nephrol. 2002; 13: 745–753. 11856780

5. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, et al. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the community. J Am Coll Cardiol. 2003; 41: 47–55. doi: 10.1016/s0735-1097(02)02663-3 12570944

6. Irie F, Iso H, Sairenchi T, Fukasawa N, Yamagishi K, Ikehara S, et al. The relationships of proteinuria, serum creatinine, glomerular filtration rate with cardiovascular disease mortality in Japanese general population. Kidney Int. 2006; 69: 1264–1271. doi: 10.1038/ 16501489

7. Ninomiya T, Kiyohara Y, Kubo M, Tanizaki Y, Doi Y, Okubo K, et al. Chronic kidney disease and cardiovascular disease in a general Japanese population: the Hisayama Study. Kidney Int. 2005; 68: 228–236. doi: 10.1111/j.1523-1755.2005.00397.x 15954912

8. Navaneethan SD, Schold JD, Arrigain S, Jolly SE, Nally JV Jr. Cause-Specific Deaths in Non-Dialysis-Dependent CKD. J Am Soc Nephrol. 2015; 26: 2512–2520. doi: 10.1681/ASN.2014101034 26045089

9. Weng PH, Hung KY, Huang HL, Chen JH, Sung PK, Huang KC. Cancer-specific mortality in chronic kidney disease: longitudinal follow-up of a large cohort. Clin J Am Soc Nephrol. 2011; 6: 1121–1128. doi: 10.2215/CJN.09011010 21511834

10. Nagai K, Yamagata K, Ohkubo R, Saito C, Asahi K, Iseki K, et al. Annual decline in estimated glomerular filtration rate is a risk factor for cardiovascular events independent of proteinuria. Nephrology (Carlton). 2014; 19: 574–580.

11. Turin TC, Coresh J, Tonelli M, Stevens PE, de Jong PE, Farmer CK, et al. Change in the estimated glomerular filtration rate over time and risk of all-cause mortality. Kidney Int. 2013; 83: 684–691. doi: 10.1038/ki.2012.443 23344477

12. Matsushita K, Selvin E, Bash LD, Franceschini N, Astor BC, Coresh J. Change in estimated GFR associates with coronary heart disease and mortality. J Am Soc Nephrol. 2009; 20: 2617–2624. doi: 10.1681/ASN.2009010025 19892932

13. Al-Aly Z, Zeringue A, Fu J, Rauchman MI, McDonald JR, El-Achkar TM, et al. Rate of kidney function decline associates with mortality. J Am Soc Nephrol. 2010; 21: 1961–1969. doi: 10.1681/ASN.2009121210 20947634

14. Shlipak MG, Katz R, Kestenbaum B, Siscovick D, Fried L, Newman A, et al. Rapid decline of kidney function increases cardiovascular risk in the elderly. J Am Soc Nephrol. 2009; 20: 2625–2630. doi: 10.1681/ASN.2009050546 19892934

15. Grams ME, Sang Y, Coresh J, Ballew SH, Matsushita K, Levey AS, et al. Candidate Surrogate End Points for ESRD after AKI. J Am Soc Nephrol. 2016; 27: 2851–2859. doi: 10.1681/ASN.2015070829 26857682

16. Lambers Heerspink HJ, Tighiouart H, Sang Y, Ballew S, Mondal H, Matsushita K, et al. GFR decline and subsequent risk of established kidney outcomes: a meta-analysis of 37 randomized controlled trials. Am J Kidney Dis. 2014; 64: 860–866. doi: 10.1053/j.ajkd.2014.08.018 25441439

17. Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014; 64: 821–835. doi: 10.1053/j.ajkd.2014.07.030 25441437

18. Sumida K, Molnar MZ, Potukuchi PK, George K, Thomas F, Lu JL, et al. Changes in Albuminuria and Subsequent Risk of Incident Kidney Disease. Clin J Am Soc Nephrol. 2017; 12: 1941–1949. doi: 10.2215/CJN.02720317 28893924

19. Carrero JJ, Grams ME, Sang Y, Arnlov J, Gasparini A, Matsushita K, et al. Albuminuria changes are associated with subsequent risk of end-stage renal disease and mortality. Kidney Int. 2017; 91: 244–251. doi: 10.1016/j.kint.2016.09.037 27927597

20. Delanaye P, Glassock RJ. Lifetime Risk of CKD: What Does It Really Mean? Clin J Am Soc Nephrol. 2015; 10: 1504–1506. doi: 10.2215/CJN.07860715 26286926

21. Inker LA, Tighiouart H, Aspelund T, Gudnason V, Harris T, Indridason OS, et al. Lifetime Risk of Stage 3–5 CKD in a Community-Based Sample in Iceland. Clin J Am Soc Nephrol. 2015; 10: 1575–1584. doi: 10.2215/CJN.00180115 26286924

22. Delanaye P, Glassock RJ, De Broe ME. Epidemiology of chronic kidney disease: think (at least) twice! Clin Kidney J. 2017; 10: 370–374. doi: 10.1093/ckj/sfw154 28617483

23. Glassock R, Delanaye P, El Nahas M. An Age-Calibrated Classification of Chronic Kidney Disease. JAMA. 2015; 314: 559–560. doi: 10.1001/jama.2015.6731 26023760

24. Nagai K, Saito C, Watanabe F, Ohkubo R, Sato C, Kawamura T, et al. Annual incidence of persistent proteinuria in the general population from Ibaraki annual urinalysis study. Clin Exp Nephrol. 2013; 17: 255–260. doi: 10.1007/s10157-012-0692-5 22971964

25. Iseki K, Asahi K, Yamagata K, Fujimoto S, Tsuruya K, Narita I, et al. Mortality risk among screened subjects of the specific health check and guidance program in Japan 2008–2012. Clin Exp Nephrol. 2017; 21: 978–985.

26. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009; 53: 982–992. doi: 10.1053/j.ajkd.2008.12.034 19339088

27. Inker LA, Levey AS, Pandya K, Stoycheff N, Okparavero A, Greene T, et al. Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysis. Am J Kidney Dis. 2014; 64: 74–85. doi: 10.1053/j.ajkd.2014.02.020 24787763

28. Jun M, Turin TC, Woodward M, Perkovic V, Lambers Heerspink HJ, Manns BJ, et al. Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis. J Am Soc Nephrol. 2015; 26: 2289–2302. doi: 10.1681/ASN.2014040396 25556165

29. Heerspink HJ, Kropelin TF, Hoekman J, de Zeeuw D, Reducing Albuminuria as Surrogate Endpoint C (2015) Drug-Induced Reduction in Albuminuria Is Associated with Subsequent Renoprotection: A Meta-Analysis. J Am Soc Nephrol 26: 2055–2064. doi: 10.1681/ASN.2014070688 25421558

30. Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014; 311: 2518–2531. doi: 10.1001/jama.2014.6634 24892770

Článek vyšel v časopise


2019 Číslo 10

Nejčtenější v tomto čísle

Tomuto tématu se dále věnují…


Zvyšte si kvalifikaci online z pohodlí domova

Léčba bolesti v ordinaci praktického lékaře
nový kurz
Autoři: MUDr. PhDr. Zdeňka Nováková, Ph.D.

Revmatoidní artritida: včas a k cíli
Autoři: MUDr. Heřman Mann

Jistoty a nástrahy antikoagulační léčby aneb kardiolog - neurolog - farmakolog - nefrolog - právník diskutují
Autoři: doc. MUDr. Štěpán Havránek, Ph.D., prof. MUDr. Roman Herzig, Ph.D., doc. MUDr. Karel Urbánek, Ph.D., prim. MUDr. Jan Vachek, MUDr. et Mgr. Jolana Těšínová, Ph.D.

Léčba akutní pooperační bolesti
Autoři: doc. MUDr. Jiří Málek, CSc.

Nové antipsychotikum kariprazin v léčbě schizofrenie
Autoři: prof. MUDr. Cyril Höschl, DrSc., FRCPsych.

Všechny kurzy
Kurzy Doporučená témata Časopisy
Zapomenuté heslo

Nemáte účet?  Registrujte se

Zapomenuté heslo

Zadejte e-mailovou adresu se kterou jste vytvářel(a) účet, budou Vám na ni zaslány informace k nastavení nového hesla.


Nemáte účet?  Registrujte se